Literature DB >> 16354964

Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma.

Susan J Moug1, Edward Leen, Paul G Horgan, Clement W Imrie.   

Abstract

BACKGROUND: Vasoactive intestinal peptide-secreting tumours (VIPomas) are rare islet cell tumours of the pancreas that can result in life-threatening biochemical abnormalities. The optimal intervention for metastatic VIPoma remains undecided. This case history documents the clinical role of radiofrequency (RF) ablation in the treatment of metastatic VIPoma. CASE HISTORY: A primary pancreatic VIPoma was diagnosed in a 61-year-old female in 1998 and a distal pancreatectomy and splenectomy were performed. She remained disease-free for 44 months when she presented as an emergency with watery diarrhoea, hypokalaemia, renal failure and an elevated serum VIP level. CT scanning showed a liver metastasis and open RF ablation was performed with complete resolution of symptoms and biochemistry within 48 h. Post-ablation imaging confirmed complete ablation of the metastasis. She remained disease-free until 22 months later when watery diarrhoea resumed and a new hepatic metastasis was seen on CT. Percutaneous RF ablation was performed and follow-up CT scan showed complete ablation of the metastasis. The patient remains disease- and symptom-free 10 months after the second RF ablation.
CONCLUSION: This case illustrates that the pronounced clinical and biochemical upset caused by metastatic VIPoma can be resolved safely, quickly and repeatedly by RF ablation. 2006 S. Karger AG, Basel and IAP

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16354964     DOI: 10.1159/000090257

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  9 in total

Review 1.  Oligometastatic Disease in Pancreatic Cancer - How to Proceed?

Authors:  Bernhard W Renz; Stefan Boeck; Falk Roeder; Christoph Trumm; Volker Heinemann; Jens Werner
Journal:  Visc Med       Date:  2017-02-10

Review 2.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

Review 3.  Treatment options of metastatic and nonmetastatic VIPoma: a review.

Authors:  Azadeh Azizian; Alexander König; Michael Ghadimi
Journal:  Langenbecks Arch Surg       Date:  2022-08-05       Impact factor: 2.895

4.  Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors.

Authors:  Edward Leen; Senthil Kumar; Shahid A Khan; Gavin Low; Keh Oon Ong; Paul Tait; Mike Averkiou
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

Review 5.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

Review 6.  Surgery for oligometastasis of pancreatic cancer.

Authors:  Fengchun Lu; Katherine E Poruk; Matthew J Weiss
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

7.  Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Eleni Papoutsi; Vasiliki Ntella; Prodromos Kanavidis; Athanasios Sioulas; Marina Tsoli; Georgios Charalampopoulos; Michail Vailas; Evangelos Felekouras
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

8.  The problems of radiofrequency ablation as an approach for advanced unresectable ductal pancreatic carcinoma.

Authors:  Raffaele Pezzilli; Claudio Ricci; Carla Serra; Riccardo Casadei; Francesco Monari; Marielda D'Ambra; Roberto Corinaldesi; Francesco Minni
Journal:  Cancers (Basel)       Date:  2010-07-01       Impact factor: 6.639

9.  Surgical resection of vasoactive intestinal peptideoma with hepatic metastasis aids symptom palliation: A case report.

Authors:  Xiaomei Zhang; Lingli Zhou; Ying Liu; Wei Li; Hongkai Gao; Yunan Wang; Baoting Yao; Daming Jiang; Peijun Hu
Journal:  Exp Ther Med       Date:  2016-01-22       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.